Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$8.26 USD
-0.25 (-2.94%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $8.28 +0.02 (0.24%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Voyager Therapeutics, Inc. [VYGR]
Reports for Purchase
Showing records 101 - 120 ( 146 total )
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
RMAT Designation a Nice to Have; July Likely to Crystallize C-Suite and Posterior Route Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Tackling Neurodegeneration With Gene Therapy; Initiating With a Buy and $30 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Upgrading to OUTPERFORM on Valuation Post Sell-Off
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Valuation looks Fair Ahead of Parkinson?s Pivotal Trial Start
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Moving to Sidelines on More Balanced Risk Reward.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Early Stage Alzheimer?s Program Outlicensed on Highly Attractive Terms
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
R-D Day Update; Pivotal Parkinson''s Trial Next in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Q3; Reevaluating VY-AADC Development Timeline for Parkinson?s, Trimming PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Voyager Therapeutics, Inc.
Industry: Medical - Generic Drugs
Sanofi Decision to Not Opt-in for VY-AADC Unlikely to be Data-Driven
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D